Candesartan

證據等級: L5

預測適應症: 10 個

Candesartan: From Hypertension to Migraine Disorder

One-Sentence Summary

Candesartan is an angiotensin II type 1 receptor blocker (ARB) widely used for hypertension and heart failure, though it is not currently registered with SAHPRA. The TxGNN model predicts it may be effective for Migraine Disorder prevention, with a prediction score of 99.97%. This direction is supported by 3 directly relevant clinical trials — including 2 completed Phase 2 RCTs — and 20 publications, spanning a 2025 Lancet Neurology landmark trial through to multiple Tier 1 international headache guidelines.

Quick Overview

Item	Content
Original Indication	Hypertension / Heart failure (established ARB class; not registered with SAHPRA)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.97%
Evidence Level	L2
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Candesartan is an angiotensin II type 1 receptor (AT1R) antagonist. Detailed mechanism of action data was not retrieved in this Evidence Pack; however, based on its well-established pharmacological profile, Candesartan selectively blocks AT1 receptors and inhibits the downstream effects of angiotensin II — including vasoconstriction, aldosterone secretion, and vascular remodelling.

The mechanistic rationale for migraine prevention is biologically plausible across several pathways. AT1R blockade in cerebrovascular smooth muscle may reduce the abnormal vasomotor fluctuations implicated in migraine onset. Candesartan may also attenuate trigeminal neurovascular inflammation — a core driver of migraine pain generation — by suppressing angiotensin II–mediated neuroinflammatory signalling. By displacing angiotensin II from AT1R, Candesartan allows relative activation of AT2 receptors, which have been associated with neuroprotection and anti-inflammatory effects. Additionally, RAAS modulation may reduce the frequency of cortical spreading depression (CSD), the neurobiological substrate of migraine aura.

Critically, these mechanistic pathways are supported by converging clinical evidence. Both Candesartan and propranolol — a first-line approved migraine preventive — act on complementary vascular regulatory pathways and are co-listed as preventive options in authoritative international headache guidelines, including those from the American Academy of Neurology (2012), the Canadian Headache Society (2012), and the American College of Physicians (2025). The TxGNN model’s high prediction score of 99.97% is therefore well-grounded in biological plausibility and clinical precedent.

Clinical Trial Evidence

Trials assessed as irrelevant to Candesartan’s role in migraine (Grade C) have been excluded from the table below.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04574713	Phase 2	Completed	450	Large multicentre, triple-blind, placebo-controlled RCT across two countries comparing Candesartan 8 mg/day vs 16 mg/day vs placebo for episodic migraine prevention. Investigated whether earlier smaller RCT findings could be confirmed at scale. Results published in Lancet Neurology (2025, PMID 40975098) — the primary confirmatory trial for this indication.
NCT00884663	Phase 2/3	Completed	72	Double-blind, placebo-controlled, triple cross-over study comparing Candesartan directly against propranolol for migraine prophylaxis. Provides head-to-head non-inferiority data against an approved first-line preventive agent.
NCT04138316	Observational	Completed	85	CandeSpartan: prospective real-world study assessing response predictors and tolerability of Candesartan in patients with episodic or chronic migraine who had previously failed ≥3 preventive drugs. Results published in Cephalalgia (2024, PMID 38663908). Enhances external validity of RCT findings.

Note: No registrations were identified in the South African National Clinical Trials Register (SANCTR) or the Pan African Clinical Trials Registry (PACTR) for Candesartan in migraine.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40975098	2025	Phase 2 RCT	The Lancet Neurology	Landmark randomised, triple-blind, placebo-controlled Phase 2 trial (n=450). Directly evaluated safety, tolerability, and efficacy of Candesartan for episodic migraine prevention. Currently the strongest single study supporting this indication.
39899861	2025	Clinical Practice Guideline	Annals of Internal Medicine	American College of Physicians guideline for pharmacological prevention of episodic migraine in outpatient settings. Provides updated evidence-graded recommendations including ARBs.
22529202	2012	Evidence-based Guideline	Neurology	American Academy of Neurology / American Headache Society guideline update on pharmacological treatment for episodic migraine prevention in adults. Lists Candesartan among evidence-supported preventive options.
22683887	2012	Clinical Guideline	Can J Neurol Sci	Canadian Headache Society migraine prophylaxis guideline. Explicitly recommends Candesartan as a preventive agent for episodic migraine based on available RCT evidence.
38057728	2023	Systematic Review / NMA	J Headache Pain	Network meta-analysis of pharmacological interventions for chronic migraine in adults. Ranks comparative effectiveness of preventive drugs and addresses uncertainty about optimal treatment selection.
37350141	2023	Systematic Review / Meta-analysis	Cephalalgia	Systematic review and meta-analysis examining blood pressure–lowering medications for episodic migraine prevention. Provides pooled efficacy estimates for the ARB class and assesses whether benefits extend beyond currently recommended agents.
38663908	2024	Observational Cohort	Cephalalgia	CandeSpartan study: real-world effectiveness, tolerability, and response predictors of Candesartan in migraine in a Spanish clinical practice cohort. Effectiveness was supported by two prior RCTs; this real-world study broadens external validity.
40571531	2025	Scoping Review	Clinical Therapeutics	Scoping review consolidating all available evidence for Candesartan in migraine management. Positioned against the backdrop of migraine’s ranking as the third leading cause of global disability.
30600979	2019	Review	Am Fam Physician	Review of migraine prophylaxis for primary care. Notes that ~38% of patients with episodic migraine would benefit from preventive therapy, yet fewer than 13% receive it — highlighting an unmet clinical need that Candesartan could help address.
33589682	2021	Retrospective Cohort	Scientific Reports	Real-world effectiveness and tolerability of Candesartan across a decade of clinical practice (2008–2019). Primary endpoint: change in monthly headache days at weeks 8–12 versus baseline. Also explored predictors of patient response.

South Africa Market Information

Candesartan is not currently registered with SAHPRA and holds no approved medicine listings in South Africa under this INN. It is therefore not commercially available through licensed South African supply channels.

Clinicians wishing to access Candesartan for migraine prevention in South Africa would need to proceed via SAHPRA’s Section 21 (unregistered medicine) access pathway. Inclusion on the National Essential Medicines List (NEML) would require a formal health technology assessment application.

Safety Considerations

Safety data including key warnings, contraindications, and drug interaction information was not retrieved in this Evidence Pack.

Please refer to the originator’s Professional Information (PI) document — or the relevant international product monograph — for complete safety information. As an ARB, Candesartan is contraindicated in pregnancy (fetopathy risk) and carries class-level considerations for renal function and potassium levels. Adverse drug reactions should be reported to SAHPRA via the MedSafety reporting platform.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 2 RCTs directly evaluating Candesartan for episodic migraine prevention — most notably the 2025 Lancet Neurology trial (n=450) — provide Level 2 evidence supporting this repurposing direction. The drug appears in several authoritative international headache guidelines and the TxGNN model’s 99.97% prediction score is well-corroborated by this clinical evidence base. The primary barriers to immediate use in South Africa are regulatory (no SAHPRA registration) rather than evidential.

To proceed, the following is needed:

Regulatory access pathway: Submit a SAHPRA Section 21 application to enable access for individual patients pending formal registration, or initiate a formal SAHPRA registration dossier for the migraine prevention indication.
Complete safety review: Obtain and review the originator PI for full contraindication, warning, and drug interaction profile — particularly teratogenicity risk (ARBs are contraindicated in pregnancy), renal function monitoring requirements, and interactions with potassium-sparing agents or NSAIDs.
Mechanism of action documentation: Retrieve formal MOA data from DrugBank (DB13919) to strengthen the mechanistic rationale in any regulatory or HTA submission.
Dose and titration protocol: Define the preferred preventive dose range (8–16 mg/day per trial evidence) and titration schedule appropriate for South African clinical practice.
Local evidence generation: Consider registering a prospective observational or interventional study with SANCTR or PACTR to generate safety and efficacy data relevant to South African patient populations and healthcare settings.
Health technology assessment: If registration is pursued, a cost-effectiveness analysis against current NEML-listed migraine preventives (e.g., propranolol, amitriptyline) will be required to support NEML inclusion.

Supplementary: Other TxGNN Predictions (Ranks 2–10)

Rank	Disease	Score	Evidence Level	Decision
2	Migraine with brainstem aura	99.96%	L3	Research Question — related migraine subtype; no dedicated trials; mechanistic rationale via brainstem AT1R expression
3	Migraine with or without aura, susceptibility to	99.94%	L2	Research Question — precision medicine angle; RAAS polymorphisms (ACE I/D) may predict ARB response
4	Pulmonary hypertension	99.93%	L4	Hold — theoretical RAAS–pulmonary vascular link, but PAH is primarily driven by ET-1/NO/prostacyclin pathways; clinical trials retrieved were irrelevant
5	Prinzmetal angina	99.91%	L5	Hold — theoretical AT1R–coronary spasm link, but calcium-channel–mediated mechanism dominates; no supporting data
6	Kyphoscoliotic heart disease	99.90%	L5	Hold — mechanical aetiology predominates; ARB intervention not feasible
7	Atrophoderma vermiculata	99.87%	L5	Hold — no biological rationale linking RAAS to this rare follicular skin disorder
8	Ulerythema ophryogenesis	99.86%	L5	Hold — highly speculative AT1R–MAPK pathway hypothesis; no supporting data
9	Benign prostatic hyperplasia	99.84%	L5	Hold — local prostatic RAAS is plausible but unvalidated clinically; would require Phase 1 exploration
10	Alopecia	99.78%	L5	Hold — purely theoretical follicular vasculature hypothesis; no preclinical or clinical evidence

This report is generated for research purposes only and does not constitute medical advice. Drug repurposing candidates require rigorous clinical validation before therapeutic application. All predictions are model-derived and must be interpreted in the context of formal evidence review.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.